Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Other Non-Current Liabilities (2020 - 2025)

Bioventus' Other Non-Current Liabilities history spans 6 years, with the latest figure at $15.3 million for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities fell 33.56% year-over-year to $15.3 million; the TTM value through Dec 2025 reached $15.3 million, down 33.56%, while the annual FY2025 figure was $15.3 million, 33.56% down from the prior year.
  • Other Non-Current Liabilities reached $15.3 million in Q4 2025 per BVS's latest filing, down from $20.5 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $30.9 million in Q3 2023 to a low of $15.3 million in Q4 2025.
  • Average Other Non-Current Liabilities over 5 years is $23.4 million, with a median of $22.8 million recorded in 2022.
  • Peak YoY movement for Other Non-Current Liabilities: tumbled 44.57% in 2022, then surged 72.58% in 2023.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $16.3 million in 2021, then grew by 6.75% to $17.4 million in 2022, then soared by 60.25% to $27.9 million in 2023, then decreased by 17.3% to $23.1 million in 2024, then tumbled by 33.56% to $15.3 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Other Non-Current Liabilities are $15.3 million (Q4 2025), $20.5 million (Q3 2025), and $21.3 million (Q2 2025).